BDBM102351 US10562854, No. F2::US8536181, F2::US9278930, F2

SMILES: Oc1cccn(Cc2cccc(Cl)c2)c1=O

InChI Key: InChIKey=VIWSANOEUHNZFR-UHFFFAOYSA-N

Data: 8 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 102351   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Egl nine homolog 1 (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	5.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Aerpio Therapeutics Inc. US Patent					Assay Description EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.				US Patent US8536181 (2013) BindingDB Entry DOI: 10.7270/Q2D21W79
					More data for this Ligand-Target Pair
Vascular endothelial growth factor A (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+5	n/a	n/a	n/a	n/a	n/a	n/a
Aerpio Therapeutics Inc. US Patent					Assay Description ELISA assay using VEGF.				US Patent US8536181 (2013) BindingDB Entry DOI: 10.7270/Q2D21W79
					More data for this Ligand-Target Pair
Egl nine homolog 1 (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	5.00E+3	n/a	n/a	n/a	n/a	7.5	n/a
Aerpio Therapeutics Inc. US Patent					Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...				US Patent US8778412 (2014) BindingDB Entry DOI: 10.7270/Q2WS8RZ9
					More data for this Ligand-Target Pair
Vascular endothelial growth factor A (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description VEGF: HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following ove...				US Patent US10562854 (2020) BindingDB Entry DOI: 10.7270/Q2668GK0
					More data for this Ligand-Target Pair
Egl nine homolog 1 [179-426] (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	5.00E+3	n/a	n/a	n/a	n/a	7.5	25
AERPIO THERAPEUTICS, INC. US Patent					Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...				US Patent US9278930 (2016) BindingDB Entry DOI: 10.7270/Q24J0CZG
					More data for this Ligand-Target Pair
Vascular endothelial growth factor A (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+5	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...				US Patent US9278930 (2016) BindingDB Entry DOI: 10.7270/Q24J0CZG
					More data for this Ligand-Target Pair
Egl nine homolog 1 (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	5.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
AERPIO THERAPEUTICS, INC. US Patent					Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...				US Patent US10562854 (2020) BindingDB Entry DOI: 10.7270/Q2668GK0
					More data for this Ligand-Target Pair
Vascular endothelial growth factor A (Homo sapiens (Human))	BDBM102351 (US10562854, No. F2 | US8536181, F2 | US9278930, F2) Show SMILES Oc1cccn(Cc2cccc(Cl)c2)c1=O Show InChI InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(15)12(14)16/h1-7,15H,8H2	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+5	n/a	n/a	n/a	n/a	n/a	n/a
Aerpio Therapeutics Inc. US Patent					Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...				US Patent US8778412 (2014) BindingDB Entry DOI: 10.7270/Q2WS8RZ9
					More data for this Ligand-Target Pair